HAM-D17 and HAM-D6 sensitivity to change in relation to desvenlafaxine dose and baseline depression severity in major depressive disorder

Pharmacopsychiatry

Volumn 43, Issue 7, 2010, Pages 271-276

  Bech, P ^a   Boyer, P ^b   Germain, J M ^c   Padmanabhan, K ^c   Haudiquet, V ^c   Pitrosky, B ^c   Tourian, K A ^c  

^a FREDERIKSBORG GENERAL HOSPITAL   (Denmark)

^b UNIVERSITY OF OTTAWA   (Canada)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESVENLAFAXINE; PLACEBO; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; O-DESMETHYLVENLAFAXINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; DRUG WITHDRAWAL; EFFECT SIZE; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; AGED; DISEASE COURSE; DOSE RESPONSE; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78049417989     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0030-1263173     Document Type: Article

References (26)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC American Psychiatric Association 1994
2. Angst J, Bech P, Boyer P, et al. Consensus conference on the methodology of clinical trials of antidepressants. Pharmacopsychiatry 1989 22 3-7
3. Bech P. Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton depression scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. Int J Neuropsychopharmacol 2001 4 337-345
4. Bech P. Applied psychometrics in clinical psychiatry: The pharmacopsychometric triangle. Acta Psychiatr Scand 2009 120 400-409
5. Bech P. Is the antidepressive effect of second-generation antidepressants a myth? Psychol Med 2010 40 181-186
6. Bech P, Allerup P, Gram LF, et al. The Hamilton depression scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand 1981 63 290-299
7. Bech P, Cialdella P, Haugh MC, et al. Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry 2000 176 421-428
8. Bech P, Gram LF, Dein E, et al. Quantitative rating of depressive states. Acta Psychiatr Scand 1975 51 161-170
9. Bech P, Kajdasz DK, Porsdal V. Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Psychopharmacology (Berl) 2006 188 273-280
10. Bech P, Tanghoj P, Cialdella P, et al. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol 2004 7 283-290
11. Bollini P, Pampallona S, Tibaldi G, et al. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry 1999 174 297-303
12. Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008 23 243-253
13. DeMartinis NA, Yeung PP, Entsuah R, et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007 68 677-688 (Pubitemid 46841850)
14. Entsuah AR, Gao B. Global benefit-risk evaluation of antidepressant action: comparison of pooled data for venlafaxine, SSRIs, and placebo. CNS Spectr 2002 7 882-888
15. Faries D, Herrera J, Rayamajhi J, et al. The responsiveness of the Hamilton depression rating scale. J Psychiatr Res 2000 34 3-10
16. Hamilton M. Development of rating scale for primary depressive illness. Br J Soc Clin Psychol 1967 6 278-296
17. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008 5 e45
18. Liebowitz M, Manley AL, Padmanabhan SK, et al. Efficacy, safety, and tolerability of desvenlafaxine 50mg/d and 100mg/d in outpatients with major depressive disorder. Curr Med Res Opin 2008 24 1877-1890
19. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979 134 382-389
20. Reddy S, Kane C, Pitrosky B, et al. Clinical utility of desvenlafaxine 50mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin 2010 26 139-150
21. Rief W, Nestoriuc Y, Weiss S, et al. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord 2009 118 1-8
22. Septien-Velez L, Pitrosky B, Padmanabhan SK, et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 2007 22 338-347
23. Thase ME, Kornstein SG, Germain J-M, et al. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr 2009 14 144-154
24. Tourian KA, Padmanabhan SK, Groark J, et al. Desvenlafaxine 50 and 100mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther 2009 31 1405-1423
25. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008 358 252-260
26. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002 287 1840-1847